Wells Fargo’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-30,434
| Closed | -$273K | – | 6749 |
|
|
2016
Q3 | $273K | Buy |
30,434
+3,949
| +15% | +$28.1K | ﹤0.01% | 4298 |
|
|
2016
Q2 | $142K | Sell |
26,485
-5,426
| -17% | -$27.8K | ﹤0.01% | 4606 |
|
|
2016
Q1 | $148K | Buy |
31,911
+10,508
| +49% | +$42.2K | ﹤0.01% | 4593 |
|
|
2015
Q4 | $111K | Sell |
21,403
-2,716
| -11% | -$15.8K | ﹤0.01% | 4849 |
|
|
2015
Q3 | $146K | Sell |
24,119
-10,479
| -30% | -$128K | ﹤0.01% | 4657 |
|
|
2015
Q2 | $546K | Buy |
34,598
+29,751
| +614% | +$361K | ﹤0.01% | 4033 |
|
|
2015
Q1 | $52K | Buy |
4,847
+1,356
| +39% | +$13.8K | ﹤0.01% | 4999 |
|
|
2014
Q4 | $37K | Sell |
3,491
-106
| -3% | -$1.04K | ﹤0.01% | 5141 |
|
|
2014
Q3 | $35K | Sell |
3,597
-18,977
| -84% | -$194K | ﹤0.01% | 5077 |
|
|
2014
Q2 | $261K | Buy |
22,574
+4,366
| +24% | +$39.8K | ﹤0.01% | 4253 |
|
|
2014
Q1 | $183K | Buy |
18,208
+18,108
| +18,108% | +$261K | ﹤0.01% | 4375 |
|
|
2013
Q4 | $1K | Sell |
100
-470,757
| -100% | -$6.48M | ﹤0.01% | 5692 |
|
|
2013
Q3 | $7.03M | Sell |
470,857
-215,080
| -31% | -$2.58M | ﹤0.01% | 1935 |
|
|
2013
Q2 | $6.41M | Buy |
+685,937
| New | +$4.65M | ﹤0.01% | 1915 |
|
Wells Fargo's RPTP Position: Q4 2016 in Review
Wells Fargo sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 30,434 shares — an estimated $273K sold.
Wells Fargo first reported a position in RPTP in Q2 2013 and held it in 14 quarters. The position peaked at $7.03M in Q3 2013. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.
- Wells Fargo reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
- Wells Fargo sold 30,434 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $273K.
- Wells Fargo first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 14 quarters.
- Wells Fargo's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $7.03M in Q3 2013.
- 0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.
Based on Wells Fargo's 13F filing for Q4 2016, filed 1 Feb 2017.